阿尔尼拉姆制药公司(ALNY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ALNY 阿尔尼拉姆制药公司

未开盘 07-21 16:00:00 EDT

271.37

-1.30

-0.48%

盘后271.92

+0.55+0.20%

19:41 EDT

最高278.30	最低270.01	成交量98.28万
今开272.40	昨收272.67	日振幅3.04%
总市值362.08亿	流通市值361.35亿	总股本1.33亿
成交额2.68亿	换手率0.74%	流通股本1.33亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ALNY","market":"US","secType":"STK","nameCN":"阿尔尼拉姆制药公司","latestPrice":271.37,"timestamp":1784664000000,"preClose":272.67,"halted":0,"volume":982811,"hourTrading":{"tag":"盘后","latestPrice":271.92,"preClose":271.37,"latestTime":"19:41 EDT","volume":57783,"amount":15680684.277,"timestamp":1784677273950,"change":0.55,"changeRate":0.002027,"amplitude":0.002027},"delay":0,"changeRate":-0.004767667876920861,"floatShares":133157589,"shares":133427910,"eps":4.0295005,"marketStatus":"未开盘","change":-1.3,"latestTime":"07-21 16:00:00 EDT","open":272.4,"high":278.3,"low":270.01,"amount":268484456.40165,"amplitude":0.030403,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":4.0295005,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1784707200000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1085630400000,"exchange":"NASDAQ","adjPreClose":272.67,"preHourTrading":{"tag":"盘前","latestPrice":272.09,"preClose":272.67,"latestTime":"09:29 EDT","volume":1808,"amount":498726.7656,"timestamp":1784640599999,"change":-0.58,"changeRate":-0.002127,"amplitude":0.025819},"postHourTrading":{"tag":"盘后","latestPrice":271.92,"preClose":271.37,"latestTime":"19:41 EDT","volume":57783,"amount":15680684.277,"timestamp":1784677273950,"change":0.55,"changeRate":0.002027,"amplitude":0.002027},"volumeRatio":0.749904,"impliedVol":0.5927,"impliedVolPercentile":0.992},"requestUrl":"/m/hq/s/ALNY","defaultTab":"news","newsList":[{"id":"1129095578","title":"异动解读｜阿尔尼拉姆制药公司盘中下跌5.04%，报268.89美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1129095578","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129095578?lang=zh_cn&edition=full","pubTime":"2026-07-18 02:35","pubTimestamp":1784313355,"startTime":"0","endTime":"0","summary":"7月17日，阿尔尼拉姆制药公司盘中下跌5.04%，报268.89美元/股，成交额1.74亿美元。阿尔尼拉姆制药公司所在的生物科技行业中，整体表现偏弱，个股中，艾伯维公司涨0.61%，安进跌2.44%，吉利德科学跌1.10%，福泰制药跌0.40%，再生元制药公司跌0.92%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125707751","title":"异动解读｜阿尔尼拉姆制药公司盘中下跌5.29%，报280.705美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1125707751","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125707751?lang=zh_cn&edition=full","pubTime":"2026-07-13 22:16","pubTimestamp":1783952164,"startTime":"0","endTime":"0","summary":"7月13日，阿尔尼拉姆制药公司盘中下跌5.29%，报280.705美元/股，成交额1.15亿美元。阿尔尼拉姆制药公司所在的生物科技行业中，个股中，艾吉纳斯公司涨142.68%，Q32 Bio Inc.涨61.6%，Moderna涨0.43%，Nuvalent涨0.04%，艾伯维公司跌0.85%。阿尔尼拉姆制药公司是一家基于RNA干扰（RNAi）技术的生物制药公司，通过RNAi选择性沉默特定基因以治疗多种人类疾病，核心产品包括用于转甲状腺素蛋白淀粉样变性的Amvuttra及Onpattro等。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106574639","title":"异动解读｜阿尔尼拉姆制药公司盘中下跌5.08%，报296.89美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1106574639","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106574639?lang=zh_cn&edition=full","pubTime":"2026-07-11 00:51","pubTimestamp":1783702305,"startTime":"0","endTime":"0","summary":"7月11日，阿尔尼拉姆制药公司盘中下跌5.08%，报296.89美元/股，成交额3.34亿美元。阿尔尼拉姆制药公司所在的生物科技行业中，个股中，艾伯维公司跌1.42%，Ionis Pharmaceuticals跌8.01%，Moderna跌11.25%，吉利德科学跌3.67%，BridgeBio Pharma跌4.18%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187899712","title":"异动解读｜阿尔尼拉姆制药公司盘中上涨15.34%，竞争对手阿斯利康心脏病后期试验失败提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1187899712","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187899712?lang=zh_cn&edition=full","pubTime":"2026-07-09 21:58","pubTimestamp":1783605534,"startTime":"0","endTime":"0","summary":"7月9日，阿尔尼拉姆制药公司盘中上涨15.34%，报361.795美元/股，成交额6.31亿美元。消息面上，竞争对手阿斯利康与Ionis Pharmaceuticals合作开发的神经疾病治疗药物Wainua，在一项针对特定心脏病患者的后期临床研究中未能达到主要终点。市场认为该试验失利为阿尔尼拉姆旗下同适应症产品扫清了潜在竞争障碍。基本面方面，阿尔尼拉姆核心产品Amvuttra上一季度净产品收入约8.27亿美元，商业化能力已获市场验证。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167833053","title":"阿尔尼拉姆制药公司股价大涨15.5%，因阿斯利康神经疾病药物Wainua心脏病后期试验失败","url":"https://stock-news.laohu8.com/highlight/detail?id=1167833053","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167833053?lang=zh_cn&edition=full","pubTime":"2026-07-09 21:35","pubTimestamp":1783604157,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司股价飙升超过15%，这一显著涨幅源于其竞争对手阿斯利康的一款药物在关键临床试验中遭遇挫折。阿斯利康与合作伙伴Ionis Pharmaceuticals开发的神经疾病治疗药物Wainua，在一项针对特定心脏病患者的后期研究中未能达到主要目标。\n市场对此反应迅速，投资者将目光投向了阿尔尼拉姆。该公司拥有针对相似适应症的在研药物，此次竞争对手的试验失利，被广泛视为为阿尔尼拉姆的产品扫清了潜在的竞争障碍，或至少推迟了其面临的直接市场挑战。这一事件凸显了生物制药领域激烈的竞争动态，单一临床结果足以引发相关公司市场估值的剧烈波动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0320765992.SGD","LU0889565916.HKD","LU0882574055.USD","ALNY","LU0109394709.USD","PBE","BK4548","BK4585","LU0114720955.EUR","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105086619","title":"异动解读｜阿尔尼拉姆制药公司盘前上涨6.11%，报336.95美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1105086619","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105086619?lang=zh_cn&edition=full","pubTime":"2026-07-09 16:02","pubTimestamp":1783584167,"startTime":"0","endTime":"0","summary":"7月9日，阿尔尼拉姆制药公司盘前上涨6.11%，报336.95美元/股，成交额15.37万美元。阿尔尼拉姆制药公司所在的生物科技行业中，个股中，艾伯维公司涨0%，福泰制药涨0.39%，吉利德科学跌0.38%，安进跌0.48%，再生元制药公司涨0%。阿尔尼拉姆制药公司是一家基于RNA干扰（RNAi）技术的生物制药公司，通过RNAi选择性沉默特定基因以治疗多种人类疾病，核心产品包括用于转甲状腺素蛋白淀粉样变性的Amvuttra及Onpattro等。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119455915","title":"异动解读｜阿尔尼拉姆制药公司夜盘上涨5.1%，报340.0美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1119455915","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119455915?lang=zh_cn&edition=full","pubTime":"2026-07-09 14:49","pubTimestamp":1783579782,"startTime":"0","endTime":"0","summary":"7月9日，阿尔尼拉姆制药公司夜盘上涨5.1%，报340.0美元/股，成交额74.26万美元。阿尔尼拉姆制药公司所在的生物科技行业中，个股中，艾伯维公司涨0.0%，福泰制药涨0.19%，吉利德科学跌0.23%，安进跌0.19%，再生元制药公司涨0%。阿尔尼拉姆制药公司是一家基于RNA干扰（RNAi）技术的生物制药公司，通过RNAi选择性沉默特定基因以治疗多种人类疾病，核心产品包括用于转甲状腺素蛋白淀粉样变性的Amvuttra及Onpattro等。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190050017","title":"异动解读｜阿尔尼拉姆制药公司盘中上涨5.01%，多重合作利好叠加生物科技板块走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1190050017","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190050017?lang=zh_cn&edition=full","pubTime":"2026-07-02 23:00","pubTimestamp":1783004400,"startTime":"0","endTime":"0","summary":"7月2日，阿尔尼拉姆制药公司盘中上涨5.01%，报316.78美元/股，成交额6771.12万美元。多重利好持续释放提振市场情绪。阿尔尼拉姆制药公司是RNA干扰疗法领域的领导者，通过RNAi技术选择性沉默致病基因，开发针对严重疾病的创新治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116794367","title":"异动解读｜阿尔尼拉姆制药公司盘中上涨5.1%，siRNA核心产品销售强劲增长获机构看好","url":"https://stock-news.laohu8.com/highlight/detail?id=1116794367","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116794367?lang=zh_cn&edition=full","pubTime":"2026-06-25 00:51","pubTimestamp":1782319896,"startTime":"0","endTime":"0","summary":"6月25日，阿尔尼拉姆制药公司盘中上涨5.1%，报302.87美元/股，成交额1.55亿美元。消息面上，近期有券商发布深度研报看好公司siRNA药物在心血管赛道的全面布局。相比之下，辉瑞口服药Tafamidis增速已回落至17%，而竞品ASO药物Eplontersen因给药频率较高，上市后放量明显落后。此外，公司在双靶点siRNA等前沿方向的布局也被视为下一个研发热点，进一步巩固其核酸药物龙头地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117880479","title":"Genesis Pharma 与 Alnylam Pharmaceuticals 协议范围扩大，现已覆盖丹麦、芬兰、挪威及瑞典","url":"https://stock-news.laohu8.com/highlight/detail?id=1117880479","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117880479?lang=zh_cn&edition=full","pubTime":"2026-06-10 19:50","pubTimestamp":1781092242,"startTime":"0","endTime":"0","summary":"Genesis Pharma 与阿尔尼拉姆制药公司（Alnylam Pharmaceuticals）的合作协议已获扩展。根据最新安排，协议所覆盖的地域范围现已将丹麦、芬兰、挪威和瑞典四国纳入其中。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0114720955.EUR","BK4548","LU0882574055.USD","LU0320765992.SGD","BK4139","LU0889565916.HKD","ALNY","LU0109394709.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193311703","title":"创生药业与阿尔尼拉姆制药就RNAi疗法在斯堪的纳维亚地区达成战略商业合作扩展","url":"https://stock-news.laohu8.com/highlight/detail?id=1193311703","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193311703?lang=zh_cn&edition=full","pubTime":"2026-06-10 19:48","pubTimestamp":1781092097,"startTime":"0","endTime":"0","summary":"创生药业宣布，已与阿尔尼拉姆制药公司就RNAi（核糖核酸干扰）疗法达成战略商业合作，并将合作范围扩展至斯堪的纳维亚地区。此举旨在加强双方在该地区的市场覆盖与商业化能力，共同推动创新疗法的可及性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0109394709.USD","LU0320765992.SGD","BK4139","LU0882574055.USD","BK4548","ALNY","BK4588","LU0889565916.HKD","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180043296","title":"阿尔尼拉姆制药与Inceptive达成战略AI合作，加速RNAi疗法研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1180043296","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180043296?lang=zh_cn&edition=full","pubTime":"2026-06-04 05:57","pubTimestamp":1780523873,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司（Alnylam Pharmaceuticals）与生物技术公司Inceptive宣布建立战略合作，旨在利用人工智能技术加速RNA干扰疗法的发现进程。这项合作潜在总价值高达20亿美元，其中包含3000万美元的预付款。\n通过结合阿尔尼拉姆在RNAi科学领域的深厚专长与Inceptive先进的AI平台，双方将共同探索和开发新型治疗分子。此举有望显著缩短药物研发周期，并为攻克复杂疾病开辟新的可能性。该合作凸显了人工智能在推动下一代生物制药创新中的关键作用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0882574055.USD","LU0109394709.USD","LU0320765992.SGD","BK4585","LU0114720955.EUR","ALNY","LU0889565916.HKD","BK4548","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118719716","title":"心衰2026大会发布新数据分析：Vutrisiran作为一线治疗方案在ATTR-CM患者群体中展现强劲且一致的临床获益，包括高疾病负担患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1118719716","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118719716?lang=zh_cn&edition=full","pubTime":"2026-05-12 14:30","pubTimestamp":1778567419,"startTime":"0","endTime":"0","summary":"在近期举行的“心衰2026”大会上公布的最新数据分析显示，Vutrisiran作为一线治疗选择，在转甲状腺素蛋白淀粉样变性心肌病（ATTR-CM）患者群体中，展现出强劲且一致的临床获益。这一积极结果覆盖了包括高疾病负担在内的广泛患者亚组，为该疗法的应用前景提供了有力支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0320765992.SGD","BK4585","BK4139","LU0114720955.EUR","LU0109394709.USD","BK4548","BK4588","LU0882574055.USD","ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163333507","title":"阿尔尼拉姆制药公司将于2026年心力衰竭大会公布新分析，凸显Vutrisiran在ATTR-CM中一致的临床特征","url":"https://stock-news.laohu8.com/highlight/detail?id=1163333507","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163333507?lang=zh_cn&edition=full","pubTime":"2026-05-04 20:30","pubTimestamp":1777897826,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司（Alnylam Pharmaceuticals）计划在2026年心力衰竭大会上展示最新分析数据，这些数据进一步证实了其在研药物Vutrisiran用于转甲状腺素蛋白淀粉样变性心肌病（ATTR-CM）治疗时展现出的稳定临床效果。\n此次公布的分析结果将强化Vutrisiran的临床价值，为患者提供新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","LU0320765992.SGD","BK4588","LU0882574055.USD","LU0109394709.USD","ALNY","BK4548","BK4585","LU0889565916.HKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154504008","title":"异动解读 | 阿尔尼拉姆制药公司盘前大涨6.25%，受财报及业务进展提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1154504008","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154504008?lang=zh_cn&edition=full","pubTime":"2026-04-30 20:07","pubTimestamp":1777550837,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司（ALNY）今日盘前股价大幅上涨6.25%，引起了市场的广泛关注。消息面上，公司于盘前披露了2026年第一季度财务业绩报告，并重点展示了在报告期内取得的多项关键业务进展。这份积极的财报和业务更新，增强了投资者对公司未来发展的信心，从而推动了股价的显著上扬。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100877819","title":"阿尔尼拉姆制药公司公布2026年第一季度财报及近期业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1100877819","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100877819?lang=zh_cn&edition=full","pubTime":"2026-04-30 20:01","pubTimestamp":1777550479,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司近日披露了2026年第一季度财务业绩报告，同时重点展示了公司在报告期内取得的多项关键业务进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY","LU0320765992.SGD","BK4588","BK4585","BK4139","LU0882574055.USD","LU0109394709.USD","BK4548","LU0114720955.EUR","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147790578","title":"财报前瞻｜阿尔尼拉姆制药公司本季度营收预计增90.11%，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1147790578","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147790578?lang=zh_cn&edition=full","pubTime":"2026-04-23 09:35","pubTimestamp":1776908112,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司将于2026年04月30日（盘前）发布最新季度财报，市场关注收入高增与盈利质量的协调性。市场一致预期显示，本季度阿尔尼拉姆制药公司营收预计为11.14亿美元，同比增长90.11%；调整后每股收益预计为0.93美元，同比增长192.63%；公司未披露本季度的毛利率与净利润或净利率的明确预测。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜阿尔尼拉姆制药公司本季度营收预计增90.11%，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154632206","title":"杰富瑞对阿尔尼拉姆制药公司启动覆盖，给予持有评级，目标价330美元，此前为买入评级及522美元目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1154632206","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154632206?lang=zh_cn&edition=full","pubTime":"2026-03-16 15:47","pubTimestamp":1773647233,"startTime":"0","endTime":"0","summary":"杰富瑞集团近日宣布，对阿尔尼拉姆制药公司启动研究覆盖，并给予其股票“持有”评级。与此同时，该机构设定了330美元的目标股价。\n这一评级与之前机构给予的“买入”评级形成对比，且目标价也从先前的高位522美元大幅下调至330美元。此番调整反映了分析师对公司未来前景的重新评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4548","BK4588","LU0109394709.USD","LU0114720955.EUR","LU0320765992.SGD","LU0882574055.USD","LU0889565916.HKD","BK4585","ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177542029","title":"Tenaya Therapeutics与Alnylam Pharmaceuticals达成研究合作，共同探索心血管疾病治疗新靶点","url":"https://stock-news.laohu8.com/highlight/detail?id=1177542029","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177542029?lang=zh_cn&edition=full","pubTime":"2026-03-05 21:36","pubTimestamp":1772717783,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics Inc（简称Tenaya）已与Alnylam Pharmaceuticals（简称Alnylam）正式签署一项研究合作协议。双方将携手致力于识别并验证针对心血管疾病治疗的新型遗传靶点，旨在推动相关疗法研发取得突破性进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNYA","BK4588","LU0114720955.EUR","BK4548","BK4539","LU0882574055.USD","LU0320765992.SGD","BK4139","LU0889565916.HKD","ALNY","LU0109394709.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137928746","title":"阿尔尼拉姆制药公司：旗下药物Amvuttra获加拿大药品管理局公共报销积极推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=1137928746","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137928746?lang=zh_cn&edition=full","pubTime":"2026-03-02 21:03","pubTimestamp":1772456597,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司近日迎来重大利好消息。加拿大负责药品评估与报销建议的关键机构——加拿大药品管理局，已对其创新药物Amvuttra给出了积极的公共报销推荐意见。\n这一推荐意味着，符合特定条件的加拿大患者未来有望通过公共医保系统获得Amvuttra的治疗，从而显著减轻经济负担。此举不仅提升了该药物的可及性，也为阿尔尼拉姆制药公司在加拿大市场的拓展注入了强劲动力。\nAmvuttra是一种基于RNA干扰技术的治疗药物，用于治疗遗传性转甲状腺素蛋白淀粉样变性伴多发性神经病。获得官方机构的报销推荐，是创新药物成功商业化并惠及更多患者的关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0882574055.USD","BK4139","BK4548","LU0889565916.HKD","ALNY","LU0114720955.EUR","LU0320765992.SGD","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alnylam.com","stockEarnings":[{"period":"1week","weight":-0.0352},{"period":"1month","weight":-0.0242},{"period":"3month","weight":-0.1262},{"period":"6month","weight":-0.2666},{"period":"1year","weight":-0.1533},{"period":"ytd","weight":-0.3176}],"compareEarnings":[{"period":"1week","weight":-0.0047},{"period":"1month","weight":0.0021},{"period":"3month","weight":0.0521},{"period":"6month","weight":0.0861},{"period":"1year","weight":0.1901},{"period":"ytd","weight":0.0973}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Alnylam Pharmaceuticals, Inc.是一家特拉华州公司，成立于2003年5月。该公司是一家研发基于RNA或RNAi干涉为新型治疗手段的生物制药公司。RNAi是一种在生物体内细胞中自然产生的选择性沉默及调控表达的特定基因。由于许多疾病是因为特定基因的不适当活动引起的，通过RNAi对于基因的选择性沉默能力可以为治疗许多人类疾病提供一种新的途径。公司认为，通过RNAi原理工作的药物有潜力成为的一种新的药物分类，诸如小分子药物、蛋白质药物以及抗体药物等。通过已经建立RNAi的知识产权以及专业技术，公司正在开发一套生物化学方法以帮助公司建立一个系统，通过该系统可以研发改进RNAi对于各种疾病的治疗方案。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.028609},{"month":2,"riseRate":0.454545,"avgChangeRate":0.002754},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.012836},{"month":4,"riseRate":0.363636,"avgChangeRate":-0.021744},{"month":5,"riseRate":0.590909,"avgChangeRate":0.038262},{"month":6,"riseRate":0.608696,"avgChangeRate":0.061553},{"month":7,"riseRate":0.652174,"avgChangeRate":0.097992},{"month":8,"riseRate":0.590909,"avgChangeRate":0.037005},{"month":9,"riseRate":0.545455,"avgChangeRate":0.034409},{"month":10,"riseRate":0.409091,"avgChangeRate":-0.042013},{"month":11,"riseRate":0.727273,"avgChangeRate":0.078577},{"month":12,"riseRate":0.454545,"avgChangeRate":0.006257}],"exchange":"NASDAQ","name":"阿尔尼拉姆制药公司","nameEN":"Alnylam Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿尔尼拉姆制药公司(ALNY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿尔尼拉姆制药公司(ALNY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿尔尼拉姆制药公司,ALNY,阿尔尼拉姆制药公司股票,阿尔尼拉姆制药公司股票老虎,阿尔尼拉姆制药公司股票老虎国际,阿尔尼拉姆制药公司行情,阿尔尼拉姆制药公司股票行情,阿尔尼拉姆制药公司股价,阿尔尼拉姆制药公司股市,阿尔尼拉姆制药公司股票价格,阿尔尼拉姆制药公司股票交易,阿尔尼拉姆制药公司股票购买,阿尔尼拉姆制药公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿尔尼拉姆制药公司(ALNY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿尔尼拉姆制药公司(ALNY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}